{"id":571939,"date":"2023-06-15T00:00:00","date_gmt":"2023-06-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0014-2023-biopharma-atopic-dermatitis-access-reimbursement-us-2023\/"},"modified":"2026-03-31T10:32:49","modified_gmt":"2026-03-31T10:32:49","slug":"acreim0014-2023-biopharma-atopic-dermatitis-access-reimbursement-us-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0014-2023-biopharma-atopic-dermatitis-access-reimbursement-us-2023\/","title":{"rendered":"Atopic Dermatitis | Access &#038; Reimbursement | US | 2023"},"content":{"rendered":"<p>The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021), including two systemic JAK inhibitors, two nonsteroidal topical therapies, and two injectable biologic drugs. Newer topical agents like Pfizer\u2019s PDE-4 inhibitor Eucrisa (crisaborole) and Incyte\u2019s topical JAK inhibitor Opzelura (ruxolitinib) are expanding treatment options for mild to moderate AD, while newer options for the treatment of moderate to severe AD include injectable targeted biologics (Sanofi \/ Regeneron\u2019s Dupixent [dupilumab] and LEO Pharma&#8217;s Adbry [tralokinumab]) and systemic JAK inhibitors (Pfizer\u2019s Cibinqo [abrocitinib] and AbbVie\u2019s Rinvoq [upadacitinib]). While Dupixent and Eucrisa, both approved in 2017, have established their niches in AD treatment, payer policies affecting more recently approved therapies will influence physician prescribing of and patient access to these newer therapies. This report will explore in depth the potential of these newer therapies to reshape the AD treatment landscape and drug market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the current prescribing practices for AD, and how are they impacted by payer policy?<\/li>\n<li>What are physicians\u2019 and payers\u2019 opinions of Opzelura, Adbry, Cibinqo, and Rinvoq, and how has their availability for AD impacted physician prescribing and payer reimbursement?<\/li>\n<li>How will dermatologists\u2019 prescribing of established agents by line of therapy shift as these new agents are incorporated into the treatment algorithm?<\/li>\n<li>As systemic JAK inhibitors are granted label expansions for AD, what do payers say about the use of indication-based formularies?<\/li>\n<li>What are payers\u2019 and physicians\u2019 perspectives on promising emerging agents such as Dermira\u2019s lebrikizumab, Chugai \/ Dermira \/ Mahuro\u2019s nemolizumab, and Arcutis\u2019s ARQ-151?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS <\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary Research:<\/strong> Survey of 100 U.S. dermatologists. Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs\/MDs).<\/p>\n<p><strong>Key Drugs Covered: <\/strong>Adbry, Cibinqo, Dupixent, Eucrisa, Olumiant, Opzelura, Rinvoq, ARQ-151, lebrikizumab, nemolizumab.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-571939","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571939\/revisions"}],"predecessor-version":[{"id":576093,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571939\/revisions\/576093"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=571939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}